Vascular Response to Isoproterenol and β2 Adrenergic Receptor Polymorphisms
Information source: Hadassah Medical Organization
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Coronary Disease
Intervention: Isoproterenol (Drug)
Phase: N/A
Status: Completed
Sponsored by: Hadassah Medical Organization Official(s) and/or principal investigator(s):
Yoseph Caraco, MD, Principal Investigator, Affiliation: Hadassah Medical Organization
Summary
Single nucleotide polymorphisms at codon 46 and 79 of the gene encoding for the ß2 adrenergic
receptor (ß2AR) modify its pharmacological properties and may alter the response to ß2AR
agonists. The goal of the present study was to evaluate the role played by the Arg16Gly and
Gln27Glu polymorphisms on isoproterenol induced relaxation of internal mammary arteries
segments ex-vivo.
Internal mammary leftover segments were collected from 96 patients undergoing coronary artery
bypass graft operation. Four rings that were prepared from each specimen were allowed to
reach equilibrium with physiological Krebs solution prior to precontraction with U46619.
Using the organ bath technique, cumulative dose response curve of isoproterenol was
constructed and mean EC50 calculated for each patient.
Clinical Details
Official title: ß2 Adrenergic Receptor Polymorphisms and Vasodilation of Internal Mammary Artery Induced by Isoproterenol
Study design: Other, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study
Primary outcome: Mean Ec50% in response to rising concentration of isoproterenol
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients scheduled to undergo coronary artery bypass graft operation
Exclusion Criteria:
- Chronic treatment with corticosteroids
Locations and Contacts
Hadassah Medical Organization, Jerusalem, Israel
Additional Information
Starting date: August 1999
Last updated: March 17, 2008
|
